Extracellular microRNAs (miRNA) are transported between organs in plasma by protective carriers, including high-density-lipoproteins (HDL). Cardiovascular disease (CVD) represents a significant health and financial burden to our society; however, miRNAs are a new class of drug targets that may be used to treat atherosclerosis. Our published reports and preliminary data suggest that HDL-miRNAs likely serve as biological hormones that regulate systemic homeostasis and have potential to be controlled to treat or prevent CVD. Atherosclerosis is a complex pathophysiology mediated by extensive cell-to-cell communication and gene regulation. The main objectives of this study are to define novel HDL-miRNA intercellular communication mechanisms and the physiological impact of HDL-miRNA communication in CVD. To complete these goals we will, i.) Map the distribution of HDL-miRNA communication and gene regulation, ii.) Identify novel HDL-miRNA target genes associated with inflammation and metabolism, iii.) Determine the role HDL-miR-223 plays in atherosclerosis, and iv.) Control HDL-miRNA communication to treat metabolic dysregulation and atherosclerosis. Collectively, this study will provide remarkable and fundamental insight into HDL biology, and defines the functional relevance and consequences of HDL-miRNA communication in health and disease in animals and humans. As constructed, these studies will take advantage of current concepts in lipoprotein biology and use state-of-the art methods and equipment, including extensive use of high-throughput sequencing.

Public Health Relevance

High-Density Lipoproteins (HDL) transport microRNAs (miRNA) between organs in an endocrine-like communication pathway. Strikingly, HDL-miRNAs are significantly altered in hypercholesterolemia and atherosclerosis in both humans and mice. Currently, it is unknown if changes to HDL-miRNAs promote or antagonize atherosclerosis; however, these projects aim to study key mechanisms of this pathway and define the cells and outcomes of cardiovascular communication in the HDL network.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
6R01HL128996-02
Application #
9104193
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Liu, Lijuan
Project Start
2015-07-02
Project End
2020-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Allen, Ryan M; Zhao, Shilin; Ramirez Solano, Marisol A et al. (2018) Bioinformatic analysis of endogenous and exogenous small RNAs on lipoproteins. J Extracell Vesicles 7:1506198
Li, Kang; Rodosthenous, Rodosthenis S; Kashanchi, Fatah et al. (2018) Advances, challenges, and opportunities in extracellular RNA biology: insights from the NIH exRNA Strategic Workshop. JCI Insight 3:
Sedgeman, Leslie R; Beysen, Carine; Allen, Ryan M et al. (2018) Intestinal bile acid sequestration improves glucose control by stimulating hepatic miR-182-5p in type 2 diabetes. Am J Physiol Gastrointest Liver Physiol :
Sheng, Quanhu; Vickers, Kasey; Zhao, Shilin et al. (2017) Multi-perspective quality control of Illumina RNA sequencing data analysis. Brief Funct Genomics 16:194-204
Guo, Yan; Vickers, Kasey; Xiong, Yanhua et al. (2017) Comprehensive evaluation of extracellular small RNA isolation methods from serum in high throughput sequencing. BMC Genomics 18:50
Guo, Yan; Strickland, Stephen A; Mohan, Sanjay et al. (2017) MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. Leuk Lymphoma 58:1-15
Beavers, Kelsey R; Werfel, Thomas A; Shen, Tianwei et al. (2016) Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies. Adv Mater 28:7984-7992
Ormseth, Michelle J; Yancey, Patricia G; Solus, Joseph F et al. (2016) Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. Arthritis Rheumatol 68:2099-105
Ormseth, Michelle J; Yancey, Patricia G; Yamamoto, Suguru et al. (2016) Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. IJC Metab Endocr 13:6-11
Michell, Danielle L; Vickers, Kasey C (2016) HDL and microRNA therapeutics in cardiovascular disease. Pharmacol Ther 168:43-52

Showing the most recent 10 out of 21 publications